Cancer Center Support Grant (CCSG)

癌症中心支持补助金 (CCSG)

• 批准号: 9378967
• 负责人: George J. Weiner
• 金额: $ 11.44万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-14 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9378967
• 关键词: Achievement; Animal Cancer Model; Animal Model; Area; B-Cell Neoplasm; B-Lymphocytes; Basic Cancer Research; Basic Science; Biological; Biological Markers; Biology; Budgets; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Etiology; Cancer Immunology Science; Cancer Model; Catchment Area; Cell Proliferation; Clinic; Clinical; Clinical Research; Clinical Services; Clinical Trials; Communities; Comprehensive Cancer Center; DNA Repair; DNA biosynthesis; Development; Diagnostic Imaging; Disease; Drug Delivery Systems; Education; Educational Activities; Evaluation; Family suidae; Fostering; Free Radicals; Funding; Genetic; Genetic Engineering; Genome; Goals; Health Services; Human; Image; Immune response; Immunologic Monitoring; Immunologic Surveillance; Investigational Therapies; Iowa; Journals; Knock-out; Laboratories; Laboratory Research; Lead; Link; Lymphoma; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Manuscripts; Metabolism; Mission; Molecular; Molecular Epidemiology; Morbidity - disease rate; Multiple Myeloma; Mutation; NCI Center for Cancer Research; Neuroendocrine Tumors; Non-Hodgkin' s Lymphoma; Oncogenes; Outcome; Oxidation-Reduction; Pain; Pancreatic Adenocarcinoma; Pathway interactions; Patient-Focused Outcomes; Peer Review; Pharmacology; Population Research; Population Sciences; Publications; Regulation; Research; Research Infrastructure; Research Peer Review; Research Personnel; Research Project Grants; Resources; Role; Services; Signal Pathway; System; T-Lymphocyte; TP53 gene; Testing; Therapeutic; Translating; Universities; Validation; anticancer research; ascorbate; base; cancer epidemiology; cancer gene expression; cancer imaging; cancer prevention; cancer therapy; college; fundamental research; imaging program; improved; innovation; inter-institutional; leukemia; malignant breast neoplasm; melanoma; member; molecular imaging; mortality; novel; novel strategies; novel therapeutics; programs; success; translational cancer research; tumor; tumorigenesis

 DESCRIPTION (provided by applicant): Cancer Genes and Pathways Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of biologically significant genetic alterations and molecular pathways that underlie cancer development and immune surveillance. The primary goal of this basic science program is to better understand fundamental mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2) cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific achievements over the prior funding period include advances in understanding mechanisms of damaged DNA repair and replication, identification and characterization of novel tumor-promoting genetic alterations and cancer gene networks, development of innovative animal models of cancer, and determination of pathways controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding for peer-reviewed research in the last budget year was $10.36 million ($2 NCI funding) and $1.99 million for non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored 353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22% (n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor research, and making major contributions to other human malignancies including leukemias, breast cancer, prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.

 描述（由申请人提供）：癌症基因和途径新重组的癌症基因和途径（CGP）计划的重点是研究癌症发展和免疫监视的生物学显着遗传改变和分子途径。科学计划的目的是更好地了解肿瘤发生和癌症免疫学的基本机制，从而定义可用作疾病生物标志物和/或创新抗癌疗法的新分子实体，这是通过以三个重叠的研究主题为中心来实现的。 1) 基因组组织、调控和癌症基因表达，2) 细胞增殖、存活和转化，以及 3) 先前资助期间的关键科学成就包括在理解受损 DNA 修复和复制机制、识别和表征方面取得的进展。 CGP 成员包括 54 名正式成员和 6 名准成员，涵盖 16 个部门（10 个基础科学、 3 个学院的年度 CGP 同行评审研究资助总额为 1,036 万美元（2 个 NCI 资助），非同行评审研究项目的 CGP 成员具有高度协作性，他们撰写或共同参与。 -在过去 4 年中撰写了 353 篇与癌症相关的同行评审出版物，其中 17% (n=59) 为程序内出版物，22% (n=77)跨项目和 32% (n=113) 机构间的论文发表在高影响力期刊上（影响因子 >10）。 （骨髓瘤和非霍奇金淋巴瘤）和神经内分泌肿瘤研究，并对其他人类恶性肿瘤包括白血病、乳腺癌、前列腺癌、黑色素瘤、胰腺癌和肝癌。